Drugs / GH21
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05183243 | Feb 2022 → Dec 2024 | colorectal cancer, head and neck neoplasm, malignant pancreatic neoplasm, non-small cell lung carcinoma | Suzhou Genhouse Bio Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07446725 | Feb 2026 → Oct 2029 expected | — | Suzhou Genhouse Bio Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06435455 | Jul 2024 → Sep 2027 expected | — | Suzhou Genhouse Bio Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06306456 | Mar 2024 → Dec 2025 overdue | non-small cell lung carcinoma | Suzhou Genhouse Bio Co., Ltd. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07318649 | Dec 2025 → Dec 2026 expected | — | Suzhou Genhouse Bio Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06322095 | Mar 2024 → Sep 2025 | — | Suzhou Genhouse Bio Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-04-13 | Suzhou Genhouse Bio Co., Ltd. | Results 勤浩医药合作伙伴沪亚生物国际在AACR年会公布SHP2抑制剂HBI-2376（GH21）临床前数据 genhousebio.com ↗
此次公布的临床前研究结果显示，在多种KRAS或EGFR突变的CDX/PDX模型中，GH21均表现出比竞品TNO-155和RMC-4550更强的效力。 |
| 2021-11-11 | Suzhou Genhouse Bio Co., Ltd. | Regulatory 勤浩医药SHP2抑制剂GH21 IND获CDE批准 genhousebio.com ↗
勤浩医药今日宣布，公司SHP2抑制剂GH21新药临床试验申请（IND），于近日获得中国国家药监局药品评审中心（CDE）批准。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-04-13 | Suzhou Genhouse Bio Co., Ltd. | 勤浩医药合作伙伴沪亚生物国际在AACR年会公布SHP2抑制剂HBI-2376（GH21）临床前数据 genhousebio.com ↗ |
| 2021-11-11 | Suzhou Genhouse Bio Co., Ltd. | 勤浩医药SHP2抑制剂GH21 IND获CDE批准 genhousebio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GH21 | “GH21 Capsule is a potent, orally active human SHP2 allosteric inhibitor.” NCT07446725 ↗ |
| Action | Inhibit | “GH21 Capsule is a potent, orally active human SHP2 allosteric inhibitor.” NCT07446725 ↗ |
| Route | Oral | “GH21 for oral administration” NCT05183243 ↗ |